Autres langues RemeGen Co., Ltd.

Actions

9995

CNE1000048G6

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:35 19/04/2024			Varia. 5j.	Varia. 1 janv.
27,7 ^HKD	+1,47 %		-14,11 %	-26,03 %

04/04	Remegen obtient la désignation Fast Track de la FDA américaine pour son médicament contre le syndrome de Sjögren primaire	MT
02/04	Remegen Co. annonce que la FDA a accordé au télitacicept la désignation de procédure accélérée pour le traitement du SSP	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	04/04
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	02/04
Remegen Plans A-Share Private Placement to Fund New Drug Development Project	29/03
RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding	29/03
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index	18/03
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024	11/03
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%	26/02
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
RemeGen's Loss to Widen in 2023	31/01
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	30/01
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares	23/01
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles	17/01
La población china vuelve a descender, con la tasa de natalidad más baja en los registros	17/01
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients	12/01
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment	28/12
RemeGen Gets Full Approval for Telitacicept	22/11
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA	22/11
RemeGen to Hike Annual Caps for Services Agreements	20/11
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology	15/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues RemeGen Co., Ltd.

Actions

9995

CNE1000048G6

Autres langues

Filtres